Findings From Pivotal Nipocalimab Phase 3 Study in a Broad Antibody Positive Population of People Living With Generalized Myasthenia Gravis (gMG) Published in The Lancet Neurology
January 30, 2025
January 30, 2025
NEW BRUNSWICK, New Jersey, Jan. 30 (TNSjou) -- Johnson and Johnson issued the following news release:
* * *
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Nipocalima . . .
* * *
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Nipocalima . . .